Hematological Malignancy Clinical Trials

12 recruiting

About Hematological Malignancy Clinical Trials

Looking for clinical trials for Hematological Malignancy? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hematological Malignancy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hematological Malignancy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 2

HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

Hematological Malignancy
Henry Ford Health System15 enrolled1 locationNCT03850366
Recruiting
Phase 1Phase 2

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Hematological Malignancy
M.D. Anderson Cancer Center64 enrolled1 locationNCT05110742
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors

Hematological Malignancy (Leukemia- Lymphoma)
Grit Biotechnology34 enrolled1 locationNCT07131254
Recruiting

A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy

Solid TumorHematological Malignancy
Inova Health Care Services100 enrolled1 locationNCT06106360
Recruiting

Membrane Target Detection for Leukemia Treatment

Hematological Malignancy
University of Missouri-Columbia50 enrolled1 locationNCT04841447
Recruiting
Not Applicable

Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials

Solid TumorHematological Malignancy
Institut Bergonié10,000 enrolled7 locationsNCT02534649
Recruiting
Phase 1Phase 2

GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies

Hematological Malignancy (Leukemia- Lymphoma)
Grit Biotechnology46 enrolled1 locationNCT06948981
Recruiting

A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

Hematological MalignancySolid Tumor Malignancy
Century Therapeutics, Inc.375 enrolled7 locationsNCT05768269
Recruiting
Not Applicable

CXCR4-targeted PET/CT Imaging in Hematological Malignancies

PET/CTHematological MalignancyCXCR4
Zhongnan Hospital300 enrolled1 locationNCT05255926
Recruiting
Phase 1

First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

Solid TumorHematological Malignancy
Onward Therapeutics150 enrolled4 locationsNCT05828459
Recruiting
Phase 1

Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies

Multiple MyelomaB-cell LymphomaHematological Malignancy
The Third Affiliated Hospital of Southern Medical University60 enrolled1 locationNCT06758713
Recruiting
Phase 2

Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors

Hematological MalignancyLymphocytopenia
The First Affiliated Hospital of Xiamen University50 enrolled1 locationNCT06584006
Recruiting
Phase 2

Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

NeutropeniaHematological Malignancy
West Virginia University55 enrolled1 locationNCT05537896
Recruiting
Phase 1

An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

Advanced Solid TumorHematological Malignancy
Shanghai Yuyao Biotech Co., Ltd.96 enrolled1 locationNCT06225856